Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Virbac S.A. (VIRP.PA)
EUR320.00
-2.00 (-0.62%)
FR PAR Healthcare Drug Manufacturers - General
Address
13e rue LID - BP 27 6511
Carros, FR
Carros, FR
CEO
Habib Ramdani
Website
corporate.virbac.com
IPO
1992-07-07
ISIN FR0000031577
Also trades on
Euronext Paris · VIRP.PA (EUR)
Other OTC · VRBCF (USD)
Description
Founded in 1968 and based in Carros, France, Virbac S.A. is a prominent developer and distributor of a wide array of animal health products and services. The company's global operations extend across France, Europe, Latin America, North America, Asia Pacific, the Middle East, and Africa, catering to both domestic companion animals and commercial livestock. Its extensive portfolio encompasses vaccines, dental hygiene products, reproductive health solutions, dermatological treatments, parasiticides, diagnostic instruments, antibiotics, and aquaculture offerings. Furthermore, Virbac supplies specialized veterinary pharmaceuticals for anesthesia, geriatric care, behavioral management, and injectable micronutrients, alongside pet food and electronic identification systems. These diverse solutions are designed to support veterinarians, agricultural producers, and individual pet owners worldwide.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
EUR320.00
-2.00 (-0.62%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4.0K
Beta
0.76
Float Shares
4.09M
Free Float %
48.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.42% | -1.10% | -3.50% | -3.11% | -2.58% | +0.28% | +8.14% | +25.79% | +34.27% | +131.36% | +127.94% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
320.00
DCF (Unlevered)
290.35
-9.3%
DCF (Levered)
427.59
+33.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
78% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 5 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.70
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
7 / 10
Strong MOAT
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - General: +6.6%+4.8% Q4'25: +14.1% (vs Q4'23)
-
EPS growth Drug Manufacturers - General: +18.2%+3.7% Q4'25: +47.2% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+10.6% ★ Q4'25: +17.6% (vs Q4'23)
-
EBIT margin Drug Manufacturers - General: +19.4%+14.9% Q4'25: +11.8% (vs Q4'23)
-
ROIC Drug Manufacturers - General: +10.2%+11.6% ★ Q4'25: +19.3% (vs Q4'23)
-
Share dilution Drug Manufacturers - General: +0.0%+0.1% Q4'25: -0.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×1.06× Q4'25: 0.61× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2001 actual |
Dec 2002 actual |
Dec 2003 actual |
Dec 2004 actual |
Dec 2005 actual |
Dec 2006 actual |
Dec 2007 actual |
Dec 2008 actual |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 4 EPS Ana. |
Dec 2027 8 Rev. Ana. 6 EPS Ana. |
Dec 2028 6 Rev. Ana. 6 EPS Ana. |
Dec 2029 5 Rev. Ana. 4 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
351.16M
est.
|
367.94M
est: 374.07M (-1.6%)
|
354.76M
est: 359.82M (-1.4%)
|
351.40M
est: 362.93M (-3.2%)
|
372.40M
est: 376.51M (-1.1%)
|
401.64M
est: 407.06M (-1.3%)
|
438.55M
est: 446.16M (-1.7%)
|
443.36M
est: 451.30M (-1.8%)
|
467.42M
est: 476.46M (-1.9%)
|
572.83M
est: 580.71M (-1.4%)
|
623.06M
est: 631.19M (-1.3%)
|
695.16M
est: 698.57M (-0.5%)
|
736.08M
est: 747.07M (-1.5%)
|
773.12M
est: 779.03M (-0.8%)
|
852.62M
est: 853.94M (-0.2%)
|
871.83M
est: 871.90M (0.0%)
|
861.88M
est: 861.70M (+0.0%)
|
868.93M
est: 868.80M (+0.0%)
|
938.34M
est: 937.80M (+0.1%)
|
934.20M
est: 937.95M (-0.4%)
|
1.06B
est: 1.06B (+0.2%)
|
1.22B
est: 1.20B (+1.6%)
|
1.25B
est: 1.34B (-6.9%)
|
1.40B
est: 1.40B (+0.0%)
|
1.46B
est: 1.47B (-0.4%)
|
1.54B
1.53B – 1.54B
+4.5% YoY
|
1.62B
1.60B – 1.67B
+5.6% YoY
|
1.71B
1.70B – 1.71B
+5.2% YoY
|
1.81B
1.79B – 1.84B
+6.2% YoY
|
1.92B
1.90B – 1.95B
+5.8% YoY
|
| EBITDA |
36.60M
est.
|
40.82M
est: 37.50M (+8.9%)
|
32.58M
est: 32.90M (-1.0%)
|
41.24M
est: 27.65M (+49.1%)
|
50.02M
est: 34.54M (+44.8%)
|
54.54M
est: 49.42M (+10.3%)
|
63.91M
est: 50.50M (+26.6%)
|
68.57M
est: 55.84M (+22.8%)
|
74.49M
est: 62.53M (+19.1%)
|
106.97M
est: 83.85M (+27.6%)
|
107.14M
est: 110.22M (-2.8%)
|
123.57M
est: 113.11M (+9.2%)
|
133.14M
est: 124.59M (+6.9%)
|
139.03M
est: 110.85M (+25.4%)
|
84.69M
est: 129.45M (-34.6%)
|
109.48M
est: 40.48M (+170.5%)
|
107.36M
est: 76.70M (+40.0%)
|
117.77M
est: 62.21M (+89.3%)
|
159.56M
est: 78.16M (+104.1%)
|
231.67M
est: 108.91M (+112.7%)
|
199.46M
est: 110.43M (+80.6%)
|
215.55M
est: 115.43M (+86.7%)
|
230.65M
est: 270.86M (-14.8%)
|
276.26M
est: 283.37M (-2.5%)
|
277.99M
est: 297.31M (-6.5%)
|
310.71M
309.52M – 312.27M
+4.5% YoY
|
328.16M
322.60M – 337.66M
+5.6% YoY
|
345.10M
344.20M – 346.01M
+5.2% YoY
|
366.65M
362.78M – 372.99M
+6.2% YoY
|
387.87M
383.78M – 394.58M
+5.8% YoY
|
| EBIT |
28.95M
est.
|
30.05M
est: 32.92M (-8.7%)
|
21.21M
est: 33.19M (-36.1%)
|
28.47M
est: 22.89M (+24.4%)
|
33.32M
est: 29.18M (+14.2%)
|
40.90M
est: 34.79M (+17.5%)
|
52.63M
est: 43.79M (+20.2%)
|
54.79M
est: 52.30M (+4.8%)
|
58.29M
est: 57.66M (+1.1%)
|
88.55M
est: 71.06M (+24.6%)
|
86.82M
est: 95.32M (-8.9%)
|
98.89M
est: 95.40M (+3.7%)
|
102.49M
est: 105.02M (-2.4%)
|
108.67M
est: 108.55M (+0.1%)
|
29.99M
est: 121.13M (-75.2%)
|
72.71M
est: 35.42M (+105.3%)
|
60.55M
est: 68.44M (-11.5%)
|
58.68M
est: 57.95M (+1.3%)
|
104.82M
est: 70.16M (+49.4%)
|
184.04M
est: 93.35M (+97.1%)
|
156.12M
est: 94.65M (+64.9%)
|
169.73M
est: 98.93M (+71.6%)
|
183.04M
est: 213.79M (-14.4%)
|
218.91M
est: 223.67M (-2.1%)
|
218.15M
est: 234.67M (-7.0%)
|
245.25M
244.31M – 246.48M
+4.5% YoY
|
259.02M
254.63M – 266.52M
+5.6% YoY
|
272.39M
271.68M – 273.11M
+5.2% YoY
|
289.40M
286.35M – 294.41M
+6.2% YoY
|
306.15M
302.92M – 311.45M
+5.8% YoY
|
| Net Income |
14.27M
est.
|
39.78M
est: 16.51M (+140.9%)
|
27.55M
est: 17.03M (+61.8%)
|
16.73M
est: 9.62M (+73.8%)
|
19.80M
est: 12.58M (+57.4%)
|
24.91M
est: 21.46M (+16.1%)
|
31.87M
est: 27.40M (+16.3%)
|
36.29M
est: 31.36M (+15.7%)
|
39.68M
est: 37.52M (+5.7%)
|
64.31M
est: 47.29M (+36.0%)
|
58.56M
est: 68.91M (-15.0%)
|
66.63M
est: 65.96M (+1.0%)
|
60.52M
est: 71.22M (-15.0%)
|
63.60M
est: 63.09M (+0.8%)
|
9.41M
est: 70.63M (-86.7%)
|
34.65M
est: 9.65M (+258.9%)
|
-2.58M
est: 34.36M (-107.5%)
|
20.10M
est: -2.57M (+881.9%)
|
51.55M
est: 21.70M (+137.6%)
|
136.04M
est: 49.12M (+177.0%)
|
113.16M
est: 49.80M (+127.2%)
|
121.97M
est: 119.47M (+2.1%)
|
121.30M
est: 141.19M (-14.1%)
|
145.29M
est: 149.95M (-3.1%)
|
150.89M
est: 150.89M (+0.0%)
|
167.15M
164.86M – 175.44M
+10.8% YoY
|
191.91M
171.73M – 203.97M
+14.8% YoY
|
209.56M
186.88M – 226.21M
+9.2% YoY
|
205.03M
202.22M – 209.64M
-2.2% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
91.71M
est.
|
—
est: 100.45M (-100.0%)
|
—
est: 93.98M (-100.0%)
|
1.30M
est: 98.65M (-98.7%)
|
1.49M
est: 107.85M (-98.6%)
|
1.60M
est: 118.79M (-98.7%)
|
—
est: 127.30M (-100.0%)
|
117.00M
est: 122.70M (-4.6%)
|
233.86M
est: 134.71M (+73.6%)
|
138.75M
est: 164.42M (-15.6%)
|
13.64M
est: 171.95M (-92.1%)
|
158.74M
est: 197.22M (-19.5%)
|
355.45M
est: 214.42M (+65.8%)
|
375.50M
est: 220.97M (+69.9%)
|
460.32M
est: 250.88M (+83.5%)
|
451.64M
est: 271.53M (+66.3%)
|
442.15M
est: 278.91M (+58.5%)
|
446.32M
est: 275.30M (+62.1%)
|
453.86M
est: 317.05M (+43.2%)
|
164.17M
est: 282.38M (-41.9%)
|
205.05M
est: 286.30M (-28.4%)
|
239.61M
est: 299.27M (-19.9%)
|
234.16M
est: 329.87M (-29.0%)
|
645.44M
est: 313.89M (+105.6%)
|
281.24M
est: 362.08M (-22.3%)
|
378.41M
376.96M – 380.30M
+4.5% YoY
|
399.65M
392.89M – 411.23M
+5.6% YoY
|
420.29M
419.19M – 421.39M
+5.2% YoY
|
446.54M
441.82M – 454.26M
+6.2% YoY
|
472.38M
467.39M – 480.55M
+5.8% YoY
|
| EPS |
1.71
est.
|
4.57
est: 1.98 (+130.6%)
|
3.16
est: 1.34 (+135.2%)
|
2.01
est: 1.66 (+21.4%)
|
2.33
est: 2.21 (+5.6%)
|
2.91
est: 2.98 (-2.4%)
|
3.60
est: 3.73 (-3.6%)
|
4.11
est: 4.01 (+2.4%)
|
4.48
est: 4.39 (+2.0%)
|
7.32
est: 6.63 (+10.4%)
|
6.83
est: 6.93 (-1.4%)
|
7.91
est: 7.75 (+2.0%)
|
7.18
est: 7.22 (-0.6%)
|
7.54
est: 7.64 (-1.4%)
|
1.12
est: 1.76 (-36.5%)
|
4.11
est: 4.17 (-1.3%)
|
-0.31
est: 3.37 (-109.2%)
|
2.39
est: 3.67 (-34.9%)
|
6.11
est: 6.93 (-11.8%)
|
16.12
est: 8.57 (+88.0%)
|
13.40
est: 13.44 (-0.3%)
|
14.44
est: 14.49 (-0.4%)
|
14.40
est: 16.84 (-14.5%)
|
17.34
est: 17.79 (-2.5%)
|
17.98
est: 18.58 (-3.2%)
|
20.32
19.65 – 20.91
+9.4% YoY
|
22.42
20.47 – 24.31
+10.3% YoY
|
24.42
22.27 – 26.96
+8.9% YoY
|
24.43
24.10 – 24.98
+0.1% YoY
|
—
— – —
-100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
304.52M
OE per share TTM
36.22
Owner's Yield
10.10%
Maintenance CapEx ratio
27.53%
Maint CapEx / Avg PPE
26.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 81 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF Dist MMS.PA | 0.45% | 3.21M | 0.40% |
| 2 | UBS MSCI EMU Small Cap UCITS ETF EUR dis UEFD.DE | 0.25% | 1.86M | 0.33% |
| 3 | iShares MSCI EMU Small Cap UCITS ETF CES1.L | 0.25% | 2.64M | 0.58% |
| 4 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.14% | 471.1K | 0.23% |
| 5 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.14% | 471.1K | 0.23% |
| 6 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.11% | 3.61M | 0.30% |
| 7 | iShares MSCI Europe Small-Cap ETF IEUS | 0.10% | 169.9K | 0.41% |
| 8 | Avantis International Small Cap Equity ETF AVDS | 0.06% | 199.5K | 0.30% |
| 9 | State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR Acc ZPRX.DE | 0.06% | 476.8K | 0.30% |
| 10 | Schwab International Small-Cap Equity ETF SCHC | 0.06% | 3.25M | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
34.3K
Shares Outstanding
8.38M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Paul Martingell | Chief Executive Officer | 574.7K | male |
| Habib Ramdani | Executive VP, Deputy CEO & CFO | 517.9K | male |
| Marc Bistuer | Executive Vice President of Compliance | 336.0K | male |
| Francesca Cortella | Executive Vice President of Human Resources | — | female |
| Giovanni Abruzzini | Executive Vice President of North America Region | — | male |
| Nathalie Pollet | Executive Vice President of Global Marketing & Market Development | — | female |
| Sandrine Brunel | Head of Corporate Communications | — | female |
| André Mathieu | Executive Vice President of Operations | — | male |
| Sophie Favini | Executive Vice President of International Region | — | female |
| Bertrand Havrileck | Executive Vice President of R&D | — | male |
| Enguerrand Dubois | Executive Vice President of Europe Region | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VIRP.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
